stoxline Quote Chart Rank Option Currency Glossary
  
Precipio, Inc. (PRPO)
6.7  0.44 (7.03%)    03-28 16:00
Open: 6.1169
High: 6.7
Volume: 10,143
  
Pre. Close: 6.26
Low: 6.0101
Market Cap: 10(M)
Technical analysis
2024-03-28 4:53:42 PM
Short term     
Mid term     
Targets 6-month :  7.82 1-year :  9.14
Resists First :  6.69 Second :  7.82
Pivot price 6.16
Supports First :  6.26 Second :  6
MAs MA(5) :  6.2 MA(20) :  6.22
MA(100) :  6.57 MA(250) :  7.86
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  52 D(3) :  25.7
RSI RSI(14): 61.7
52-week High :  15.42 Low :  4.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PRPO ] has closed It is unclear right now based on current values. 43.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.71 - 6.74 6.74 - 6.76
Low: 5.95 - 5.98 5.98 - 6
Close: 6.65 - 6.7 6.7 - 6.75
Company Description

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Headline News

Sat, 23 Mar 2024
Precipio (NASDAQ:PRPO) Shares Pass Below 200-Day Moving Average of $6.58 - Defense World

Fri, 15 Mar 2024
Precipio (NASDAQ:PRPO) Share Price Crosses Below 200-Day Moving Average of $6.61 - Defense World

Thu, 16 Nov 2023
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven? - Yahoo Finance

Fri, 22 Sep 2023
Precipio (NASDAQ: PRPO) to jump 2,000% at the open - nominal price change, technical - Dhaka Tribune

Thu, 21 Sep 2023
Precipio announces 1-for-20 reverse stock split to regain Nasdaq compliance (NASDAQ:PRPO) - Seeking Alpha

Sun, 13 Aug 2023
Precipio, Inc.'s (NASDAQ:PRPO) Shares Not Telling The Full Story - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Diagnostics & Research
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 3.6 (%)
Held by Institutions 10.4 (%)
Shares Short 10 (K)
Shares Short P.Month 9 (K)
Stock Financials
EPS -7.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 9.36
Profit Margin -68.4 %
Operating Margin -32.1 %
Return on Assets (ttm) -26.7 %
Return on Equity (ttm) -58 %
Qtrly Rev. Growth 104 %
Gross Profit (p.s.) 0
Sales Per Share 9.33
EBITDA (p.s.) -5.48
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -0.9
PEG Ratio -0.1
Price to Book value 0.71
Price to Sales 0.71
Price to Cash Flow -1.85
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android